HRP20240469T1 - Fc-optimizirana anti-cd25 antitijela za tumor-specifično istrošenje stanica - Google Patents
Fc-optimizirana anti-cd25 antitijela za tumor-specifično istrošenje stanica Download PDFInfo
- Publication number
- HRP20240469T1 HRP20240469T1 HRP20240469TT HRP20240469T HRP20240469T1 HR P20240469 T1 HRP20240469 T1 HR P20240469T1 HR P20240469T T HRP20240469T T HR P20240469TT HR P20240469 T HRP20240469 T HR P20240469T HR P20240469 T1 HRP20240469 T1 HR P20240469T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17161717 | 2017-03-17 | ||
| GBGB1710879.6A GB201710879D0 (en) | 2017-07-06 | 2017-07-06 | Methods and compounds for tumour-specific cell depletion |
| GBGB1714429.6A GB201714429D0 (en) | 2017-09-07 | 2017-09-07 | Compounds and methods for tumour-specific cell depletion |
| EP18711313.9A EP3596123B1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240469T1 true HRP20240469T1 (hr) | 2024-07-19 |
Family
ID=61655786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240469TT HRP20240469T1 (hr) | 2017-03-17 | 2018-03-13 | Fc-optimizirana anti-cd25 antitijela za tumor-specifično istrošenje stanica |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11879014B2 (https=) |
| EP (1) | EP3596123B1 (https=) |
| JP (2) | JP2020514363A (https=) |
| KR (1) | KR20190130137A (https=) |
| CN (1) | CN110869388B (https=) |
| AU (1) | AU2018233976B2 (https=) |
| BR (1) | BR112019017017A2 (https=) |
| CA (1) | CA3056506A1 (https=) |
| CL (1) | CL2019002624A1 (https=) |
| CR (1) | CR20190477A (https=) |
| DK (1) | DK3596123T3 (https=) |
| ES (1) | ES2975063T3 (https=) |
| FI (1) | FI3596123T3 (https=) |
| HR (1) | HRP20240469T1 (https=) |
| HU (1) | HUE065999T2 (https=) |
| IL (1) | IL269081B1 (https=) |
| LT (1) | LT3596123T (https=) |
| MX (1) | MX2019010974A (https=) |
| MY (1) | MY208220A (https=) |
| PE (1) | PE20191812A1 (https=) |
| PL (1) | PL3596123T3 (https=) |
| RS (1) | RS65351B1 (https=) |
| SG (1) | SG11201908578YA (https=) |
| SI (1) | SI3596123T1 (https=) |
| WO (1) | WO2018167104A1 (https=) |
| ZA (1) | ZA201904980B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| KR102909650B1 (ko) * | 2018-03-13 | 2026-01-08 | 터스크 테라퓨틱스 리미티드 | 종양 특이적 세포 고갈에 대한 항-cd25 |
| CA3120096A1 (en) | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Cd25 antibodies |
| EP3880698A4 (en) | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
| EP3972997A1 (en) * | 2019-05-20 | 2022-03-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Novel anti-cd25 antibodies |
| PL3932949T3 (pl) * | 2019-06-10 | 2025-11-24 | Shandong Boan Biotechnology Co., Ltd. | Przeciwciało anty-cd25 i jego zastosowanie |
| BR112022020521A2 (pt) | 2020-04-10 | 2023-03-07 | Rakuten Medical Inc | Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos |
| WO2021228218A1 (zh) | 2020-05-14 | 2021-11-18 | 江苏恒瑞医药股份有限公司 | 抗cd25抗体、其抗原结合片段及其医药用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| EP4247497A1 (en) * | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| WO2022106663A1 (en) * | 2020-11-20 | 2022-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| WO2022182483A1 (en) * | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| KR20230154012A (ko) | 2021-03-01 | 2023-11-07 | 에프. 호프만-라 로슈 아게 | 신규 바이오마커 및 이의 용도 |
| TW202319400A (zh) | 2021-09-02 | 2023-05-16 | 瑞士商赫孚孟拉羅股份公司 | 用於治療aml之抗體 |
| US20250257141A1 (en) | 2022-04-26 | 2025-08-14 | Hoffmann-La Roche Inc. | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| CA3260932A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CD25-SPECIFIC ANTIBODIES AND THEIR USES |
| CN119451978A (zh) | 2022-07-01 | 2025-02-14 | 神经基因治疗公司 | Neo-2/15变体及其用于优先刺激T调节细胞的用途 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| EP4662238A1 (en) | 2023-02-06 | 2025-12-17 | F. Hoffmann-La Roche AG | Combination therapy and uses thereof |
| CN116087499B (zh) * | 2023-02-20 | 2023-10-31 | 深圳裕康医学检验实验室 | 一种癌样本的染色方法及试剂盒 |
| CN120314588B (zh) * | 2025-05-21 | 2025-10-17 | 成都蓉生药业有限责任公司 | 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US7438907B2 (en) | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| AR062435A1 (es) | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| PL3498730T3 (pl) * | 2009-12-21 | 2026-04-07 | Regeneron Pharmaceuticals, Inc. | Humanizowane myszy fc gamma r |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| MX349662B (es) | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
| EP2970488A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Biotechnology Ltd | Anti-cd25 antibodies and their uses |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| MX2015012563A (es) | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anticuerpos anti-cd25 y sus usos. |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20220032642A (ko) | 2016-04-07 | 2022-03-15 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| MX2020008768A (es) | 2018-03-13 | 2020-10-08 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25. |
-
2018
- 2018-03-03 US US16/494,962 patent/US11879014B2/en active Active
- 2018-03-13 RS RS20240376A patent/RS65351B1/sr unknown
- 2018-03-13 LT LTEPPCT/EP2018/056312T patent/LT3596123T/lt unknown
- 2018-03-13 HR HRP20240469TT patent/HRP20240469T1/hr unknown
- 2018-03-13 PE PE2019001847A patent/PE20191812A1/es unknown
- 2018-03-13 PL PL18711313.9T patent/PL3596123T3/pl unknown
- 2018-03-13 MX MX2019010974A patent/MX2019010974A/es unknown
- 2018-03-13 SG SG11201908578Y patent/SG11201908578YA/en unknown
- 2018-03-13 ES ES18711313T patent/ES2975063T3/es active Active
- 2018-03-13 BR BR112019017017-0A patent/BR112019017017A2/pt unknown
- 2018-03-13 EP EP18711313.9A patent/EP3596123B1/en active Active
- 2018-03-13 AU AU2018233976A patent/AU2018233976B2/en active Active
- 2018-03-13 CA CA3056506A patent/CA3056506A1/en active Pending
- 2018-03-13 SI SI201831085T patent/SI3596123T1/sl unknown
- 2018-03-13 HU HUE18711313A patent/HUE065999T2/hu unknown
- 2018-03-13 FI FIEP18711313.9T patent/FI3596123T3/fi active
- 2018-03-13 WO PCT/EP2018/056312 patent/WO2018167104A1/en not_active Ceased
- 2018-03-13 CR CR20190477A patent/CR20190477A/es unknown
- 2018-03-13 MY MYPI2019005313A patent/MY208220A/en unknown
- 2018-03-13 CN CN201880018976.8A patent/CN110869388B/zh active Active
- 2018-03-13 KR KR1020197030283A patent/KR20190130137A/ko not_active Ceased
- 2018-03-13 DK DK18711313.9T patent/DK3596123T3/da active
- 2018-03-13 JP JP2019550705A patent/JP2020514363A/ja active Pending
-
2019
- 2019-07-29 ZA ZA2019/04980A patent/ZA201904980B/en unknown
- 2019-09-02 IL IL269081A patent/IL269081B1/en unknown
- 2019-09-13 CL CL2019002624A patent/CL2019002624A1/es unknown
-
2024
- 2024-01-25 JP JP2024009215A patent/JP2024050684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL269081A (en) | 2019-11-28 |
| MY208220A (en) | 2025-04-24 |
| LT3596123T (lt) | 2024-03-25 |
| FI3596123T3 (fi) | 2024-04-17 |
| CA3056506A1 (en) | 2018-09-20 |
| JP2024050684A (ja) | 2024-04-10 |
| AU2018233976B2 (en) | 2025-03-20 |
| EP3596123B1 (en) | 2024-01-10 |
| IL269081B1 (en) | 2026-01-01 |
| SI3596123T1 (sl) | 2024-05-31 |
| HUE065999T2 (hu) | 2024-06-28 |
| PL3596123T3 (pl) | 2024-06-24 |
| SG11201908578YA (en) | 2019-10-30 |
| CN110869388A (zh) | 2020-03-06 |
| EP3596123A1 (en) | 2020-01-22 |
| ZA201904980B (en) | 2026-03-25 |
| US11879014B2 (en) | 2024-01-23 |
| BR112019017017A2 (pt) | 2020-04-14 |
| DK3596123T3 (da) | 2024-02-26 |
| KR20190130137A (ko) | 2019-11-21 |
| CN110869388B (zh) | 2024-09-20 |
| PE20191812A1 (es) | 2019-12-26 |
| JP2020514363A (ja) | 2020-05-21 |
| US20200010554A1 (en) | 2020-01-09 |
| NZ756984A (en) | 2025-08-29 |
| RS65351B1 (sr) | 2024-04-30 |
| MX2019010974A (es) | 2020-08-03 |
| AU2018233976A1 (en) | 2019-10-31 |
| CL2019002624A1 (es) | 2020-04-03 |
| ES2975063T3 (es) | 2024-07-03 |
| WO2018167104A1 (en) | 2018-09-20 |
| CR20190477A (es) | 2020-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240469T1 (hr) | Fc-optimizirana anti-cd25 antitijela za tumor-specifično istrošenje stanica | |
| TWI793162B (zh) | 抗體 | |
| IL272572A (en) | Antibody compositions for tumor treatment | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| HRP20220649T1 (hr) | Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| CA3078413A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| HRP20220629T1 (hr) | Anti-cd73 antitijela i njihove upotrebe | |
| JP2018520657A5 (https=) | ||
| HRP20221284T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2020514363A5 (https=) | ||
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| CA3092589A1 (en) | Antibodies binding to vista at acidic ph | |
| SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| JP2019513725A5 (https=) | ||
| HRP20200679T1 (hr) | Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji | |
| CN112638948B (zh) | 在酸性pH下结合至VISTA的抗体 | |
| JP2022514179A (ja) | 新規アゴニスト抗ｔｎｆｒ２抗体分子 | |
| CN109310755A (zh) | Pd-l1和kdr的双特异性结合蛋白 | |
| JP2024502035A (ja) | Ｔｎｆｒ２に対する抗体およびそれの使用 | |
| CA3225254A1 (en) | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer | |
| TW202124448A (zh) | 於酸性pH結合VISTA之抗體 | |
| US20250002600A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination therapy |